Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?

The microfilaricidal anthelmintic drug ivermectin (IVM) has been used since 1988 for treatment of parasitic infections in animals and humans. The discovery of IVM’s ability to inactivate the eukaryotic importin α/β1 heterodimer (IMPα/β1), used by some viruses to enter the nucleus of susceptible host...

Descripción completa

Detalles Bibliográficos
Autores principales: Dicks, Leon M. T., Deane, Shelly M., Grobbelaar, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881049/
https://www.ncbi.nlm.nih.gov/pubmed/35218001
http://dx.doi.org/10.1007/s12602-022-09925-5
_version_ 1784659375303950336
author Dicks, Leon M. T.
Deane, Shelly M.
Grobbelaar, Matthew J.
author_facet Dicks, Leon M. T.
Deane, Shelly M.
Grobbelaar, Matthew J.
author_sort Dicks, Leon M. T.
collection PubMed
description The microfilaricidal anthelmintic drug ivermectin (IVM) has been used since 1988 for treatment of parasitic infections in animals and humans. The discovery of IVM’s ability to inactivate the eukaryotic importin α/β1 heterodimer (IMPα/β1), used by some viruses to enter the nucleus of susceptible hosts, led to the suggestion of using the drug to combat SARS-CoV-2 infection. Since IVM has antibacterial properties, prolonged use may affect commensal gut microbiota. In this review, we investigate the antimicrobial properties of IVM, possible mode of activity, and the concern that treatment of individuals diagnosed with COVID-19 may lead to dysbiosis.
format Online
Article
Text
id pubmed-8881049
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-88810492022-02-28 Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis? Dicks, Leon M. T. Deane, Shelly M. Grobbelaar, Matthew J. Probiotics Antimicrob Proteins Article The microfilaricidal anthelmintic drug ivermectin (IVM) has been used since 1988 for treatment of parasitic infections in animals and humans. The discovery of IVM’s ability to inactivate the eukaryotic importin α/β1 heterodimer (IMPα/β1), used by some viruses to enter the nucleus of susceptible hosts, led to the suggestion of using the drug to combat SARS-CoV-2 infection. Since IVM has antibacterial properties, prolonged use may affect commensal gut microbiota. In this review, we investigate the antimicrobial properties of IVM, possible mode of activity, and the concern that treatment of individuals diagnosed with COVID-19 may lead to dysbiosis. Springer US 2022-02-25 2022 /pmc/articles/PMC8881049/ /pubmed/35218001 http://dx.doi.org/10.1007/s12602-022-09925-5 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Dicks, Leon M. T.
Deane, Shelly M.
Grobbelaar, Matthew J.
Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
title Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
title_full Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
title_fullStr Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
title_full_unstemmed Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
title_short Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
title_sort could the covid-19-driven increased use of ivermectin lead to incidents of imbalanced gut microbiota and dysbiosis?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881049/
https://www.ncbi.nlm.nih.gov/pubmed/35218001
http://dx.doi.org/10.1007/s12602-022-09925-5
work_keys_str_mv AT dicksleonmt couldthecovid19drivenincreaseduseofivermectinleadtoincidentsofimbalancedgutmicrobiotaanddysbiosis
AT deaneshellym couldthecovid19drivenincreaseduseofivermectinleadtoincidentsofimbalancedgutmicrobiotaanddysbiosis
AT grobbelaarmatthewj couldthecovid19drivenincreaseduseofivermectinleadtoincidentsofimbalancedgutmicrobiotaanddysbiosis

Ejemplares similares